Conditional survival in head and neck squamous cell carcinoma - Results from the SEER dataset 1973-1998
Conditional survival in head and neck squamous cell carcinoma - Results from the SEER dataset 1973-1998
复制标题
DOI：
10.1002/cncr.22563
复制
发表时间：
2007-04-01
期刊：
影响因子：
6.2
通讯作者：
Rosenthal, David I.
中科院分区：
文献类型：
--
作者：
Fuller, Clifton D.;Wang, Samuel J.;Rosenthal, David I.
背景。头颈鳞状细胞癌 (HNSCC) 患者的生存统计数据通常是从诊断时开始计算的。不太常用的条件生存（CS）分析诊断后存活一段时间的患者的生存情况。 CS 分析为癌症幸存者提供有用的预后信息。使用大规模癌症登记数据寻找 HNSCC 的估计基线 CS 参数。访问从监测、流行病学和最终结果 (SEER) 计划中确定的 HNSCC 病例，以确定 1973 年至 1998 年间诊断的病例。进行五年观察、相对和累积 CS 计算，并按部位、疾病程度和年龄进行二次分层。结果。所有地点的总体 5 年观察生存率从诊断时起的 76,181 名患者的 47.8% 增加到 3 年生存的 43,985 名患者的 64.4%，此后趋于平稳。 CS 增幅最大的是口咽癌，在监测的第一个十年中增加了一倍多 (26.5%-60%)。远处疾病的CS呈10年增加（17.4%-60.4%），而局部疾病的CS基本保持不变，范围为66.1%至68.5%；对于诊断时年龄超过 65 岁的患者，其范围为 39.9-52.9%，而诊断时 < 65 岁的患者范围为 53.8-73.5%。结论。国内 HNSCC 队列的基准 CS 估计是根据 SEER 数据库开发的。 CS 是一种有用的工具，可帮助临床医生预测诊断后存活 1 年或以上的患者死于 HNSCC 的可能性。
BACKGROUND. Survival statistics for patients with head and neck squamous cell carcinomas (HNSCC) are commonly calculated from the time of diagnosis. The less commonly employed conditional survival (CS) analyzes survival for patients who have survived a period of time after diagnosis. Useful prognostic information for cancer survivors is provided by CS analysis. Estimated baseline CS parameters for HNSCC were sought using large-scale cancer registry data.METHODS. HNSCC cases identified from the Surveillance, Epidemiology, and End Results (SEER) Program were accessed to identify those diagnosed between 1973 and 1998. Five-year observed, relative, and cumulative CS calculations were performed, with secondary stratification by site, extent of disease, and age.RESULTS. The overall 5-year observed survival for all sites increased from 47.8% for 76,181 included patients from the time of diagnosis to 64.4% for those 43,985 patients alive at 3 years, and thereafter plateaus. The greatest increase in CS was for oropharyngeal cancers, which more than doubled over the first decade of surveillance (26.5%-60%). Distant disease showed a 10-year increase in CS (17.4%-60.4%), whereas localized disease CS was essentially static, ranging from 66.1% to 68.5%; for those over 65 at diagnosis it ranged from 39.9-52.9%, whereas patients < 65 years at diagnosis ranged from 53.8-73.5%.CONCLUSIONS. Benchmark CS estimates for domestic HNSCC cohorts were developed from the SEER database. CS is a useful tool to assist clinicians in predicting the probability of demise from HNSCC for patients surviving 1 or more year after diagnosis.